Skyrizi, a biologic medication, plays a pivotal role in treating adults with conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This article delves into its dosing schedules, safety protocols, and patient support options, offering healthcare providers the insights needed to optimize patient care and manage potential side effects effectively.
Understanding Skyrizi Prescribing Information
Skyrizi, a biologic medication, is primarily prescribed for adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis. It is crucial for healthcare providers to understand the prescribing information to ensure safe and effective treatment for patients. Skyrizi is administered through injections or intravenous infusions, depending on the condition being treated (source).
Dosing and Administration
Skyrizi’s dosing schedule is designed to fit conveniently into patients’ routines. For psoriasis and psoriatic arthritis, it is administered quarterly after two initial starter doses, each consisting of a 150 mg/mL injection beneath the skin. Patients have the option to use the Skyrizi Pen or a pre-filled syringe, which can be administered at home after proper training or in a healthcare setting (source).
For Crohn’s disease, Skyrizi is initially administered through three intravenous infusions at a healthcare facility, each consisting of a 600 mg dose. Maintenance doses are then administered at home using the Skyrizi On-Body Injector (OBI), which delivers either a 180 mg/1.2 mL or 360 mg/2.4 mL subcutaneous injection every eight weeks (source).
Safety and Monitoring
Safety is a critical aspect of Skyrizi prescribing. Patients should be screened for tuberculosis (TB) before starting treatment and monitored for signs of infection during and after treatment. Skyrizi may lower the immune system’s ability to fight infections, increasing the risk of serious infections. It is contraindicated in patients with a history of serious hypersensitivity reactions to risankizumab-rzaa or its excipients (source).
Additionally, Skyrizi can cause liver problems, particularly in patients treated for Crohn’s disease or ulcerative colitis. Regular liver function tests are recommended, and treatment may be halted if liver issues arise. Patients should report symptoms such as rash, nausea, and jaundice to their healthcare provider immediately (source).
Patient Considerations and Support
Patients should inform their healthcare provider of any medical conditions, infections, or if they are pregnant or breastfeeding. Skyrizi may interact with vaccines and other medications, so it is important to discuss any recent or planned vaccinations. Live vaccines should be avoided due to the increased risk of infection (source).
AbbVie, the manufacturer of Skyrizi, offers a co-pay assistance program for eligible patients with commercial insurance. Additional support for medication costs may be available through AbbVie’s Patient Access Support program (source).
Why You Should Learn More About Skyrizi Prescribing Today
Understanding the essential prescribing information for Skyrizi is vital for healthcare providers to ensure the safe and effective treatment of patients with conditions like psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. With its unique dosing schedules and administration methods, Skyrizi offers flexibility and convenience for patients. However, it is crucial to monitor for potential side effects and interactions with other medications. By staying informed about Skyrizi, healthcare providers can better support their patients in managing their conditions and improving their quality of life.